1. Home
  2. REVB vs UK Comparison

REVB vs UK Comparison

Compare REVB & UK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • REVB
  • UK
  • Stock Information
  • Founded
  • REVB 2020
  • UK 2015
  • Country
  • REVB United States
  • UK China
  • Employees
  • REVB N/A
  • UK N/A
  • Industry
  • REVB Biotechnology: Pharmaceutical Preparations
  • UK Business Services
  • Sector
  • REVB Health Care
  • UK Consumer Discretionary
  • Exchange
  • REVB Nasdaq
  • UK Nasdaq
  • Market Cap
  • REVB 2.6M
  • UK 2.3M
  • IPO Year
  • REVB N/A
  • UK N/A
  • Fundamental
  • Price
  • REVB $3.05
  • UK $1.13
  • Analyst Decision
  • REVB
  • UK
  • Analyst Count
  • REVB 0
  • UK 0
  • Target Price
  • REVB N/A
  • UK N/A
  • AVG Volume (30 Days)
  • REVB 39.6K
  • UK 46.1K
  • Earning Date
  • REVB 05-08-2025
  • UK 05-27-2025
  • Dividend Yield
  • REVB N/A
  • UK N/A
  • EPS Growth
  • REVB N/A
  • UK N/A
  • EPS
  • REVB N/A
  • UK N/A
  • Revenue
  • REVB N/A
  • UK $23,924,045.00
  • Revenue This Year
  • REVB N/A
  • UK N/A
  • Revenue Next Year
  • REVB N/A
  • UK N/A
  • P/E Ratio
  • REVB N/A
  • UK N/A
  • Revenue Growth
  • REVB N/A
  • UK N/A
  • 52 Week Low
  • REVB $2.36
  • UK $1.00
  • 52 Week High
  • REVB $60.80
  • UK $2.60
  • Technical
  • Relative Strength Index (RSI)
  • REVB 49.28
  • UK 51.01
  • Support Level
  • REVB $2.87
  • UK $1.08
  • Resistance Level
  • REVB $3.32
  • UK $1.36
  • Average True Range (ATR)
  • REVB 0.20
  • UK 0.07
  • MACD
  • REVB 0.02
  • UK 0.00
  • Stochastic Oscillator
  • REVB 47.18
  • UK 25.51

About REVB Revelation Biosciences Inc.

Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).

About UK Ucommune International Ltd

Ucommune International Ltd is a flexible office space provider and manager based in the People's Republic of China (PRC). The company offers long-term leasing, on-demand, and short-term leasing solutions to freelancers, start-up entrepreneurs, small and medium enterprises, and corporations. They provide fully-serviced and well-furnished office spaces on a flexible basis. The members of the Ucommune community, which includes individuals and enterprises registered on the U bazaar mobile app, can avail of these services. The company has three operating segments: Workspace membership, Marketing and branding services, and Other services. Marketing and branding services generate the majority of the company's revenue.

Share on Social Networks: